9342-8530 Québec Inc.
9342-8530 Québec Inc. DGCRF Peers
See (DGCRF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DGCRF | $0.00 | +0.00% | 21.5K | 0.00 | $0.05 | N/A |
| BMXXY | $12.95 | +0.00% | 13.5B | 27.19 | $0.42 | +0.90% |
| EBOSY | $41.94 | +0.00% | 2.4B | 25.68 | $1.83 | +1.14% |
| XVIPY | $7.50 | -2.60% | 945M | N/A | N/A | N/A |
| EBRCZ | $0.55 | +0.00% | 204.4M | -4.57 | -$0.12 | N/A |
| TRXDW | $0.15 | -11.76% | 40.1M | N/A | N/A | N/A |
| NVNBW | $0.40 | +33.33% | 7M | -0.21 | -$1.95 | N/A |
| GWPC | $0.00 | +0.00% | 52K | -0.01 | -$0.01 | N/A |
| SXHHF | $0.00 | -0.00% | 38.1K | -0.01 | -$0.01 | N/A |
| KKUR | $0.00 | +0.00% | 8.2K | N/A | N/A | N/A |
Stock Comparison
DGCRF vs BMXXY Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, BMXXY has a market cap of 13.5B. Regarding current trading prices, DGCRF is priced at $0.00, while BMXXY trades at $12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas BMXXY's P/E ratio is 27.19. In terms of profitability, DGCRF's ROE is -1.11%, compared to BMXXY's ROE of +0.10%. Regarding short-term risk, DGCRF is more volatile compared to BMXXY. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs EBOSY Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, EBOSY has a market cap of 2.4B. Regarding current trading prices, DGCRF is priced at $0.00, while EBOSY trades at $41.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas EBOSY's P/E ratio is 25.68. In terms of profitability, DGCRF's ROE is -1.11%, compared to EBOSY's ROE of +0.08%. Regarding short-term risk, DGCRF is more volatile compared to EBOSY. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs XVIPY Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, XVIPY has a market cap of 945M. Regarding current trading prices, DGCRF is priced at $0.00, while XVIPY trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas XVIPY's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to XVIPY's ROE of +0.10%. Regarding short-term risk, DGCRF is more volatile compared to XVIPY. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs EBRCZ Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, EBRCZ has a market cap of 204.4M. Regarding current trading prices, DGCRF is priced at $0.00, while EBRCZ trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas EBRCZ's P/E ratio is -4.57. In terms of profitability, DGCRF's ROE is -1.11%, compared to EBRCZ's ROE of -2.89%. Regarding short-term risk, DGCRF is more volatile compared to EBRCZ. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs TRXDW Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, TRXDW has a market cap of 40.1M. Regarding current trading prices, DGCRF is priced at $0.00, while TRXDW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas TRXDW's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to TRXDW's ROE of -5.59%. Regarding short-term risk, DGCRF is more volatile compared to TRXDW. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs NVNBW Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, NVNBW has a market cap of 7M. Regarding current trading prices, DGCRF is priced at $0.00, while NVNBW trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas NVNBW's P/E ratio is -0.21. In terms of profitability, DGCRF's ROE is -1.11%, compared to NVNBW's ROE of -0.51%. Regarding short-term risk, DGCRF is more volatile compared to NVNBW. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs GWPC Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, GWPC has a market cap of 52K. Regarding current trading prices, DGCRF is priced at $0.00, while GWPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas GWPC's P/E ratio is -0.01. In terms of profitability, DGCRF's ROE is -1.11%, compared to GWPC's ROE of N/A. Regarding short-term risk, DGCRF is more volatile compared to GWPC. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs SXHHF Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, SXHHF has a market cap of 38.1K. Regarding current trading prices, DGCRF is priced at $0.00, while SXHHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas SXHHF's P/E ratio is -0.01. In terms of profitability, DGCRF's ROE is -1.11%, compared to SXHHF's ROE of +1.13%. Regarding short-term risk, DGCRF is more volatile compared to SXHHF. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs KKUR Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, KKUR has a market cap of 8.2K. Regarding current trading prices, DGCRF is priced at $0.00, while KKUR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas KKUR's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to KKUR's ROE of N/A. Regarding short-term risk, DGCRF is more volatile compared to KKUR. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs OMRX Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, OMRX has a market cap of 5.3K. Regarding current trading prices, DGCRF is priced at $0.00, while OMRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas OMRX's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to OMRX's ROE of -0.15%. Regarding short-term risk, DGCRF is more volatile compared to OMRX. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs SCIE Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, SCIE has a market cap of 4.9K. Regarding current trading prices, DGCRF is priced at $0.00, while SCIE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas SCIE's P/E ratio is -0.01. In terms of profitability, DGCRF's ROE is -1.11%, compared to SCIE's ROE of +0.00%. Regarding short-term risk, DGCRF is more volatile compared to SCIE. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs IBXG Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, IBXG has a market cap of 2K. Regarding current trading prices, DGCRF is priced at $0.00, while IBXG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas IBXG's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to IBXG's ROE of N/A. Regarding short-term risk, DGCRF is more volatile compared to IBXG. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs DMSI Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, DMSI has a market cap of 1.9K. Regarding current trading prices, DGCRF is priced at $0.00, while DMSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas DMSI's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to DMSI's ROE of -0.32%. Regarding short-term risk, DGCRF is more volatile compared to DMSI. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs AAXT Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, AAXT has a market cap of 1.6K. Regarding current trading prices, DGCRF is priced at $0.00, while AAXT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas AAXT's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to AAXT's ROE of +0.54%. Regarding short-term risk, DGCRF is more volatile compared to AAXT. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs XCRP Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, XCRP has a market cap of 1.5K. Regarding current trading prices, DGCRF is priced at $0.00, while XCRP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas XCRP's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to XCRP's ROE of -3.49%. Regarding short-term risk, DGCRF is more volatile compared to XCRP. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs BMGP Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, BMGP has a market cap of 1.3K. Regarding current trading prices, DGCRF is priced at $0.00, while BMGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas BMGP's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to BMGP's ROE of -0.50%. Regarding short-term risk, DGCRF is more volatile compared to BMGP. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs IMRSQ Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, IMRSQ has a market cap of 626. Regarding current trading prices, DGCRF is priced at $0.00, while IMRSQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas IMRSQ's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to IMRSQ's ROE of -1.30%. Regarding short-term risk, DGCRF is more volatile compared to IMRSQ. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs STBV Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, STBV has a market cap of 472. Regarding current trading prices, DGCRF is priced at $0.00, while STBV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas STBV's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to STBV's ROE of -1.13%. Regarding short-term risk, DGCRF is more volatile compared to STBV. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs OMDD Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, OMDD has a market cap of 310. Regarding current trading prices, DGCRF is priced at $0.00, while OMDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas OMDD's P/E ratio is N/A. In terms of profitability, DGCRF's ROE is -1.11%, compared to OMDD's ROE of N/A. Regarding short-term risk, DGCRF is more volatile compared to OMDD. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.
DGCRF vs QMED Comparison
DGCRF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DGCRF stands at 21.5K. In comparison, QMED has a market cap of 17. Regarding current trading prices, DGCRF is priced at $0.00, while QMED trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DGCRF currently has a P/E ratio of 0.00, whereas QMED's P/E ratio is -0.00. In terms of profitability, DGCRF's ROE is -1.11%, compared to QMED's ROE of N/A. Regarding short-term risk, DGCRF is more volatile compared to QMED. This indicates potentially higher risk in terms of short-term price fluctuations for DGCRF.